Evidence map›Paper›PMID 39931207›Full record

ArticleFrontiers in oncology2024

Case report: Near-complete response to neratinib-based treatment in HR-positive

Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ünal Metin TokatPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Ashkan AdibiPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Esranur AydınPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Şevval Nur BilgiçPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Eylül ÖzgüPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.
Onur TutarDepartment of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Mutlu DemirayPrecision Oncology Center, Medicana Health Group, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy. Although this regimen exhibits high rates of response and disease control in both HR+ and HR- cohorts, some patients could have intrinsic or develop acquired resistance to trastuzumab and/or pertuzumab. Here, we achieved a near-complete response in HR+

Indexed as

breast cancercancer genomicsHER2 antibody-drug conjugates (HER2 ADC)molecular tumor board (MTB)neratinibprecision oncologytrastuzumab deruxtecan

Identifiers

PMID39931207
PMCPMC11808248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.